ArticleFuture oncology (London, England)2021
Development and validation of the Therapy Preference Scale to understand patients´ systemic cancer treatment preferences.
Article in Future oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults With AML.American journal of hematology · 2025Trial
- Age and sex-based differences in therapy preferences among patients with cancer: evidence from a novel therapy preference scale.Ecancermedicalscience · 2026Article
- Development and validation of the renal cancer scale among the system of quality of life instruments for cancer patients QLICP-RE (V2.0): a multicenter longitudinal study.BMC nephrology · 2025Article
- Developing a National Study That Integrates the Geriatric Assessment into the Care of Older Patients with Myeloid Malignancies.Current oncology reports · 2024Review
- Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?Future oncology (London, England) · 2022Article
- Advances and unanswered questions in management of acute myeloid leukemia in older adults: A glimpse into the future.Journal of geriatric oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We incorporated questions related to safety, effectiveness and other characteristics of systemic cancer treatment into a self-report questionnaire - the Therapy Preference Scale - that captures patients´ preferences. The authors asked 20 experts to assess content validity and an additional 20 experts, patients and community members to examine face validity and guide revisions. Key revisions included shortening the length, clarifying constructs and providing details to explain the context and trade-offs necessary to balance the risks and benefits of cancer treatment. The content validity index for the final questionnaire was 1.0, indicating that all questions were relevant. Reviewers expressed that the questionnaire would serve an important purpose. Experts, patients and community members guided revisions of the questionnaire and documented its value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.